TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07017036: An Open- Label, Multicentre, Phase III Clinical Comparative Study to Evaluate the Efficacy, Safety and Pharmacokinetic Properties of Human Normal Immunoglobulin in Patients With Primary Immunodeficiency Disease

Sponsor: Virchow Group · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 44 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,213,140

Rescue Site Savings

+$2,792,430

Unlock Full NCT07017036 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07017036 Rescue Dossier →